Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21564605 | 0.84 | KDM4E (0.39) | CHRM4 | |
| SCHEMBL21553062 | 0.79 | PIM2 (0.39) | LRRK2ALDH1A1 | |
| SCHEMBL21553159 | 0.77 | PIM2 (0.41) | ALDH1A1 | |
| SCHEMBL21552843 | 0.74 | SYK (0.31) | SYK | |
| SCHEMBL21552876 | 0.74 | LRRK2 (0.34) | MGLLPDE10ALRRK2SYKCHRM4 | |
| SCHEMBL21553154 | 0.73 | GRIA1 (0.36) | MGLLSYKALDH1A1 | |
| SCHEMBL21552857 | 0.70 | KLKB1 (0.34) | PDE10A | |
| SCHEMBL21552890 | 0.70 | PTGS2 (0.37) | MGLLSYKALDH1A1 | |
| SCHEMBL21564773 | 0.70 | LRRK2 (0.34) | MGLLPDE10ALRRK2SYK | |
| SCHEMBL21564484 | 0.66 | AKT1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790867-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | Imago Biosciences. Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3790867-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217972-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MGLL 4641/4885PDE10A 4205/4885LRRK2 3461/4885 |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MGLL 4641/4885PDE10A 4205/4885LRRK2 3461/4885 |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1A, KDM1B, KDM2A | MGLL 4582/4885PDE10A 4168/4885LRRK2 3325/4885 |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MGLL 4641/4885PDE10A 4205/4885LRRK2 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.